Vascular Dynamics, Inc. Initiates "First in Human" Clinical Study of Its MobiusHDTM Device for the Treatment of Drug Resistant HypertensionSeptember 23, 2013 8:31 am | by The Associated Press | News | Comments
Vascular Dynamics, Inc. (VDI) announced today the first patient has been treated with the MobiusHD device; a catheter-delivered implant designed for the treatment of drug resistant hypertension. Dr. Chandan Devireddy of Emory University School of Medicine treated the first patient in the FDA-approved CALM-FIM_US Study.
Researchers at the University of Leicester and Glenfield Hospital have successfully used a novel “paper-clip” sized vascular coupling device to tackle resistant high blood pressure. The operation was carried out on Monday 16 September at Glenfield Hospital by Professor André Ng, Professor of Cardiac Electrophysiology at the University of Leicester and Consultant Cardiologist at Glenfield Hospital.
Researchers at MIT have developed a microfluidic device that mimics the flow of cancer cells through a system of blood vessels. Using high-resolution time-lapse imaging, the researchers captured the moments as a cancer cell squeezes its way through a blood vessel wall into the surrounding extracellular matrix.
With a few flicks of a light switch--on-off-on-off--Stanford University's Oscar Abilez is one step closer to changing the lives of millions. Why? Because as a focused speck of light turns on and off in Abilez's lab, a cluster of heart cells begins to expand and contract. He demonstrates that he can control the rhythm of a heart using just light.
Sapheon Inc. announced today that it submitted the first module of the pre-market approval (PMA) application for the VenaSeal® Sapheon Closure System to the U.S. Food and Drug Administration (FDA). The submission places Sapheon on track for timely FDA review and expected product launch in the first half of 2015.
Teleflex Launches ARROW JACC with Chlorag+ard Technology, the First and Only Long-Term Antimicrobial and Antithrombogenic CVCSeptember 19, 2013 5:00 pm | by Business Wire | News | Comments
Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, has announced the launch of the new ARROW ® JACC with Chlorag + ard ® Technology. The ARROW ® JACC (Jugular Axillo-subclavian Central Catheter) with Chlorag + ard ® Technology is a small-french size antimicrobial and antithrombogenic catheter that is designed for both acute and long-term use.
The WaveCrest LAA Occluder is an implantable device that seals off the LAA opening so clots cannot escape into the blood stream and cause a stroke. It is a one-time treatment option for patients who would otherwise be on a lifetime regimen of anticoagulation therapy.
Coherex Medical Inc. announced it has received CE Mark approval for its Coherex WaveCrest LAA Occlusion System. Atrial fibrillation (AF) is the most common cardiac arrhythmia in today’s aging population, effecting nearly 6 million individuals in the US alone.
The CE marked TriGuard is the only device designed to cover all three aortic cerebral branches to minimize the risk of cerebral damage during Transcatheter Aortic Valve Replacement (TAVR) and other cardiovascular procedures. It is the only system designed for placement via one of two femoral artery access ports.
Medical device maker Boston Scientific (NYSE:BSX) issued new warnings on its Cognis and Teligen implantable cardioverter defibrillators, advising physicians to watch out for premature battery depletion in older models. The problematic implants are no longer available and haven't been manufactured since December 2009...
Todd Dunlap, 62, arrived at Ronald Reagan UCLA Medical Center's emergency room on Aug. 8 suffering from shortness of breath, fatigue and extreme cold. When a CT scan revealed a 24-inch clot stretching from his legs into his heart, doctors feared the mass could break loose and lodge in his lungs, blocking oxygen and killing him instantly.
Boston Scientific agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest. The settlement covers patent infringement cases over coronary stent technology in the U.S., the U.K., Germany and Holland, according to an OrbusNeich press release.
The National Institutes of Health has awarded Georgia Tech a $2-million research grant to unravel the mechanical forces at play in lymphedema, a poorly understood disease with no cure and little hope for sufferers. Lymphedema develops when the body fails to circulate lymphatic fluid, a mixture of immune cells, proteins, and lipids.
Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced the PRECISION Registry, an ongoing study aimed at collecting data on the patterns of use, safety and effectiveness in the delivery and manipulation of percutaneous coronary intervention (PCI) devices.
Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first patient implant in the Company's U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure.
A world’s first electronic smart pump which aims to increase the survival chances of victims of chronic heart failure is being developed by researchers at Nottingham Trent University and Nottingham University Hospitals NHS Trust. The smart aortic graft would be implanted into a removed section of the aorta.
On this episode of The Pulse, brought to you by MDT TV, we’re removing brain tumors with robots, using MetaboShield to help obesity, regenerating heart tissue, and pairing glucometers with smartphones for ease of use.
El Camino Hospital Enrolls Second Patient in Global Clinical Trial Evaluating the Medtronic CoreValve® System in Intermediate Risk Patients with Aortic Valve DiseaseSeptember 11, 2013 3:38 pm | by Business Wire | News | Comments
El Camino Hospital, in partnership with the Taft Center for Clinical Research and the Fogarty Clinical Research Institute, both a part of the Fogarty Institute for Innovation, announced today that it has enrolled its second patient in a global clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk for open-heart surgery.
Any time a disruptive technology comes along, prior generations of similar technologies are impacted. In the consumer market, customers generally adopt new technology rapidly if the price is right. For higher-value equipment, though, prior generations may find a new lease on life while customers wait until new technology price points come down.
W. L. Gore & Associates (Gore) today announced that the US Food and Drug Administration (FDA) has approved the Conformable GORE® TAG® Thoracic Endoprosthesis for endovascular repair of acute and chronic Type B dissections of the descending thoracic aorta.
SynCardia Systems, Inc. announced today that Matthew Green, the UK's 1st patient to be discharged with the SynCardia temporary Total Artificial Heart, has been successfully bridged to transplant after almost two years of support. Green, his wife and their 7-year-old son celebrated his new beginning with a holiday.
CardiacAssist announced the launch of the Protek17 Arterial Cannula, a key component of the TandemHeart temporary circulatory support platform used to rest the heart and circulate blood for patients with severe cardiac dysfunction. Protek17 is designed for improved patient safety and ease of use...
Whole-body MRI may serve as a valuable noninvasive tool for assessing the risk of heart attack and stroke in diabetic patients, according to a new study published online in the journal Radiology. Diabetes is a metabolic disease characterized by an increased concentration of glucose in the blood.
The famed Framingham Heart Study lost 40% of its budget to sequestration, which means layoffs and closures are on the way for the nation's longest-running cardiovascular disease trial. The study lost $4 million of its annual $9 million budget thanks to automatic funding cuts that took effect amid federal sequestration...
European Launch of New Version of Codman Neuro’s Revive SE Thrombectomy Device for Treatment of Acute Ischemic StrokeSeptember 9, 2013 2:06 pm | by Codman Neuro | News | Comments
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.